Current reports
6-K
Emerald Health Therapeutics Establishes Partnership with Spanish Greenhouse Grower for GMP-Certified Cannabis
17 Mar 21
6-K
Emerald Health Therapeutics Announces Intention to List on Canadian Securities Exchange
10 Mar 21
6-K
Current report (foreign)
18 Feb 21
6-K
Emerald Health Therapeutics Receives $20.5M Payment from Village Farms and Outlines Growth Plans
9 Feb 21
6-K
Current report (foreign)
5 Feb 21
6-K
Current report (foreign)
13 Jan 21
6-K
Emerald Health Therapeutics' Partner STENOCARE Makes First Delivery of Medical Cannabis Oil to Swedish Patients
29 Dec 20
6-K
Current report (foreign)
17 Dec 20
6-K
Emerald Health Therapeutics Terminates Agreement for Sale of Quebec Cannabis Business
4 Dec 20
6-K
Emerald Health Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
2 Dec 20
Registration and prospectus
15-15D
Suspension of duty to report
1 Apr 21
RW
Registration withdrawal request
29 Mar 21
SUPPL
Supplemental materials (foreign)
28 Mar 19
F-10/A
Registration of securities (Canada) (amended)
15 Mar 19
F-10/A
Registration of securities (Canada) (amended)
13 Mar 19
F-10/A
Registration of securities (Canada) (amended)
27 Feb 19
F-10
Registration of securities (Canada)
20 Feb 19
F-X
Appointment of agent for service of process by issuers registering securities
20 Feb 19
Proxies
No filings